跳至主要内容
临床试验/NCT01214291
NCT01214291撤回3 期

Phase III Randomized, Double-Blind, Placebo Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate 80 mg for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer on Androgen Deprivation Therapy

GTx2 个研究点 分布在 1 个国家开始时间: 2011年3月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
撤回
发起方
GTx
试验地点
2
主要终点
To confirm the efficacy of toremifene 80mg compared with placebo in the reduction in the risk of new bone fracture occurrences in men with prostate cancer on androgen deprivation therapy as measured by semiquantitative assessment of vertebral fractures

研究概览

简要总结

The purpose of this study is to determine whether Toremifene Citrate is effective in reducing the risk of bone fractures in men with prostate cancer who are on Androgen Deprivation Therapy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
50 Years 至 80 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • give voluntary signed informed consent
  • have histologically documented prostate cancer
  • have been on ADT treatment for 6 months prior to randomization or intermittent LHRHa for preceeding 12 months
  • expected to continue LHRHa therapy uninterrupted for the next 12 months
  • have total testosterone levels less than 50 ng/dL
  • Have BMD of lumbar spine or femoral neck at or below the BMD thresholds
  • have a Zubrod performance status <or equal to 1
  • subject weight <300 lbs(<136 kg)
  • agree to complete a daily diary of medication intake
  • agree not to take excluded medications throughout the trial
  • agree to use an effective method of contraception
  • have adequate bone marrow, liver and renal functions

排除标准

  • Currently or previously exposed
  • within the past 5 years to intravenous bisphosphonates, strontium ranelate or Denosumab
  • for more than 3 years to oral bisphosphonates
  • within the last 45 days to PTH or PTH derivative, anabolic steroids or testosterone, SERMs, calcitonin, calcitriol or oral gluccorticoids
  • have any disease or condition that would preclude an accurate evaluation of radiographs of the thoracic or lumbar spine
  • have <8 evaluable vertebrae
  • have a BMD T score <-4 at the lumbar spine or total hip or femoral neck
  • have any history of other carcinomas within the last 5 years
  • Serum PSA > 5ng/mL at baseline under ADT
  • have Paget's disease, Cushing's disease, chronic hepatitis or cirrhosis or rheumatoid arthritis
  • have active uncontrolled systemic viral, bacterial or fungal infections
  • have a clinically significant concurrent illness or psychological, familial, sociological, geograhical or other condition that would not permit adequate follow-up and compliance
  • received treatment with other investigational agents within 30 days
  • taking finasteride, dutasteride, danazol or testosterone like substances
  • taking herbal medicines or dietary supplements
  • have a history of thromboembolic disease including DVT or pulmonary embolus
  • have a QTcF of > or equal to 450 msec or congenital or acquired QTc prolongation
  • calcicum urolithiasis prohibiting the use of vitamin D

结局指标

主要结局

To confirm the efficacy of toremifene 80mg compared with placebo in the reduction in the risk of new bone fracture occurrences in men with prostate cancer on androgen deprivation therapy as measured by semiquantitative assessment of vertebral fractures

时间窗: 36 months

次要结局

未报告次要终点

研究者

发起方
GTx
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Efficacy and Safety Study of Toremifene Citrate for... | 临床试验